MedTrace Logo

Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military

NCT02640989 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 292

Last updated 2015-12-29

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and immunogenicity of three seasonal trivalent influenza vaccines (TIVs)manufactured by Glaxosmith Kline (GSK), Beijing Sinovac Biotech (Sinovac) and Shenzhen Sanofi Pasteur (Pasteur) in Chinese healthy servicemen. Using imported GSK's TIV as control, to compare it with other two domestic TIVs in Chinese healthy servicemen.

Conditions

Interventions

BIOLOGICAL

Seasonal trivalent influenza vaccine, Anflu®

Seasonal trivalent influenza vaccine manufactured by Sinovac Co., Ltd.

BIOLOGICAL

Seasonal trivalent influenza vaccine, VAXIGRIP

Seasonal trivalent influenza vaccine manufactured by PasteurSanofi Pasteur

BIOLOGICAL

Seasonal trivalent influenza vaccine, Fluarix

Seasonal trivalent influenza vaccine manufactured by GlaxoSmithKline Biologicals

Sponsors & Collaborators

  • Center for Disease Prevention and Control of Beijing Military Region

    lead OTHER

Principal Investigators

  • Dongqi Gao, PhD · Center for Disease Prevention and Control of Beijing Military Region

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
34 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2014-10-31
Completion
2015-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02640989 on ClinicalTrials.gov